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This is the first report of in vivo pneumococcal penicillin MIC drift from 4.0 to 16.0 mg/liter, possibly
associated with alterations in the pbp1a gene. The case presented here is of an infant with early onset recurrent
pneumonia and chronic bronchitis requiring repeated antibiotics.
The relationship between antibiotic use, the proliferation
and spread of antibiotic-resistant pneumococci, and the rate of
de novo emergence of resistance is poorly understood. Aus-
tralia’s level of pneumococcal penicillin resistance increased
from 1% in 1989 to 25% in 1997 (3). More judicious antibiotic
use is currently advocated in most developed countries, follow-
ing similar trends worldwide. Young Australian Aboriginal
children in disadvantaged communities demonstrate high cu-
mulative incidence rates of severe bacterial respiratory disease,
including chronic suppurative otitis media (10 to 40%) (A. J.
Leach, P. S. Morris, G. McCallum, C. Wigger, and the
PROMPT and PRIORiTI Investigators, Int. Symp. Pneumo-
cocci Pneumococcal Dis., abstr. PO8 47A, p. 94, 2002), chronic
suppurative lung disease (1 to 5%), and invasive pneumococcal
disease (1 to 4%) (7, 18). Repeated courses of antibiotics are
often required in our region (10). In such children, the rela-
tionship between antibiotic use and absolute rates of disease
and disease outcomes is not known.
In April 1996 a randomized placebo-controlled triple-blind
trial of long-term (up to 6 months) amoxicillin treatment (50
mg/kg/day) for prevention of acute otitis media with perfora-
tion and chronic suppurative otitis media commenced in a
remote Aboriginal community. The study was unblinded in
August 2001. Enrolled infants were examined (by P. S. Morris),
and nasopharyngeal swabs were collected monthly (8). Routine
culture methods were used. This case study is of a child en-
rolled at 82 days of age and randomized at 193 days of age.
Pneumococcal isolates were serotyped with antisera from
the Statens Serum Institut, Copenhagen, Denmark. The MICs
were determined by the E-test (AB Biodisk). For PCR studies,
DNA was prepared using a slight modification of a method
described elsewhere (12). Enterobacterial repetitive intergenic
consensus (ERIC) PCR fingerprinting (19) and pbp1a and
pbp2b gene fingerprinting were performed as described previ-
ously (4, 5).
Recurrent bronchiolitis and pneumonia delayed randomiza-
tion (to the placebo group) of this child until 193 days of age.
Assessments occurred at ages 95, 129, 163, 193, and 219 days,
with collection of nasopharyngeal swabs. Between 17 and 193
days of age the child also made 27 clinic presentations, was
admitted to the hospital four times with lower respiratory tract
infections, and was prescribed 88 days of -lactam antibiotics.
Compliance with oral antibiotics was estimated as being a
minimum of 23%. At age 219 days, the child was diagnosed
with chronic suppurative lung disease and commenced long-
term antibiotic therapy. Bronchitis and bilateral otitis media
with effusion have persisted.
At age 163 days the nasopharyngeal swab culture showed
dual pneumococcal serotypes 6B (E-test penicillin MIC of 0.5
mg/liter and ceftriaxone MIC of 0.2 mg/liter) and 14 (E-test
penicillin MIC of 4 mg/liter and ceftriaxone MIC of 3.0 mg/
liter). At ages 193 days and 219 days, swab cultures showed a
heavy growth of serotype 14 pneumococci with penicillin MICs
of 16 mg/liter and ceftriaxone MICs of 4.0 and 6.0 mg/liter,
respectively. The high MIC and the uniqueness of this isolate
in Australia was confirmed by Jan Bell of the Australian Group
on Antimicrobial Resistance. ERIC typing patterns for the
three serotype 14 isolates with penicillin MICs of 4, 16, and 16
mg/liter were identical but unique in this population (five
ERIC types were allocated to the 25 serotype 14 isolates re-
covered from children in the same community between April
1996 and October 1997). Restriction fragment length polymor-
phism analysis revealed identical pbp2b patterns for the three
isolates; however, the two high-MIC isolates had identical
pbp1a patterns that were different from the pbp1a profile of the
lower-MIC isolate. The HaeIII cut of the 2.45-kb PCR product
for the isolate with a MIC of 16 mg/liter produced bands at 1.3,
0.6, and 0.4 kb, whereas HaeIII repeatedly failed to cut pbp1a
of the isolate for which the MIC was 4 mg/liter.
Subsequent nasopharyngeal swabs at ages 394 and 452 days
both contained multidrug-resistant serotype 6B with a penicil-
lin MIC of 2.0 mg/liter. To date, high-level penicillin-resistant
serotype 14 pneumococci have not been detected in other
infants or children living in this community. The child’s mother
was carrying pneumococci on three occasions, at infant ages
129 days, 163 days, and 193 days; all isolates tested were fully
susceptible to penicillin.
Reports of pneumococci with penicillin MICs of 16 mg/liter
or more are extremely rare. To our knowledge this is the first
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such isolate to be reported in Australia and the first report of
in vivo drift from a 4 mg/liter MIC to 16 mg/liter to be de-
scribed in the medical literature (2, 13). The ordered multistep
process of penicillin resistance development seems to begin
with an alteration of pbp2x, followed by pbp2b and then pbp1a
(14). Mechanisms other than penicillin-binding protein alter-
ations may be involved (15, 16). We now show that in vivo the
final step towards the highest-level MIC may be associated
with further alterations to pbp1a.
The relative contributions by clonal (organisms) or horizon-
tal (genes) mechanisms to the spread of resistance are un-
known. For pneumococci, clonal spread has been described
globally (11, 17) and locally within this child’s community and
beyond (1, 9). In the case presented, a highly resistant clone
colonized in almost pure culture. However, subsequent spread
in the community was not detected either in the short or long
term, despite extensive antibiotic use within the community.
The failure of this highly resistant clone to spread may indicate
that organisms with extremely high MICs, probably mediated
by low-affinity PBP1A, are not stable in natural populations.
Whether the antibiotics used directly influenced these in vivo
genetic events is not known. It may be that in children with a
high bacterial load, such as those living in disadvantaged pop-
ulations where infections commence early in life, the rate of
transformation is greater, regardless of antibiotic selective
pressure. The dilemma facing health practitioners in these
areas is what constitutes appropriate antibiotic use in this era
of increasing antibiotic resistance (6). More longitudinal data
are needed to improve our understanding of how antibiotic-
resistant strains arise and spread and of the clinical implica-
tions of policies that aim to reduce antibiotic use, particularly
in populations with high rates of bacterial infection.
We thank the family involved, the Tiwi Health Board, and the
NHMRC.
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